anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Welchol
Trial phase: Phase 2
SMILES: C=CCN.C=CCNCCCCCCCCCC.C=CCNCCCCCC[N+](C)(C)C.Cl.ClCC1CO1.[Cl-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Participants received colesevelam 1.875 g twice daily
Eligibility criteria:
Inclusion Criteria:

Patients with D-IBS
Aged 18-65 years
No abdominal surgery (except appendectomy or cholecystectomy as long as patients IBS-diarrhea symptoms preceded the cholecystectomy

Exclusion Criteria:

Participants with known chronic liver disease or Aspartate aminotransferase (AST) or Alanine transaminase (ALT) > 2.0 X upper limit of normal
Hypertriglyceridemia and pancreatitis by history
Diabetes or hypoglycemia
Significant coagulation disorder
History of bowel obstruction
Serum triglycerides >500 mg/dL
History of vitamin A, D, E, or K deficiencies
Intervention: MK-0941 mesylate
Trial phase: Phase 1
SMILES: CCS(=O)(=O)c1ccc(Oc2cc(OC(C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1.CS(=O)(=O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Oral administration of a single 40-mg dose of [^14C]MK-0941 (160 µCi) to adult male subjects with type 2 diabetes.
Eligibility criteria:
Inclusion Criteria:

Subject has been diagnosed with type 2 diabetes, and is being treated with diet and exercise or with an oral anti-hyperglycemic agent
Subject is willing to follow the American Heart Association diet and exercise program throughout the study
Subject is a nonsmoker and/or has not used nicotine products for at least 6 months

Exclusion Criteria:

Subject has a history of stroke, seizures, or major neurological disorder
Subject has a history of neoplastic disease
Subject has recently had abnormal bowel habits, such as diarrhea, loose stools or constipation
Subject has a history of type 1 diabetes mellitus
Subject has received insulin within the past 12 weeks
Subject has a recent history of eye infection
Subject has been diagnosed with glaucoma or is blind
Subject consumes more than 3 alcoholic beverages per day
Subject consumes more than 6 servings of coffee, tea, cola per day
Subject has had major surgery, donated or lost blood in the past 4 weeks
Subject has multiple or severe allergies to any food or drugs
Intervention: Latrepirdine
Trial phase: Phase 3
SMILES: Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: Dimebon (latrepirdine) 10 milligram (mg) tablet orally three times a day for 1 week (titration period), followed by dimebon (latrepirdine) 20 mg tablet orally three times a day up to Week 26.
Eligibility criteria:
Inclusion Criteria:

Are men and women ≥ 50 years of age with a diagnosis of Alzheimers disease.
Have a Mini-Mental State Exam between 5 and 14 inclusive.
Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study.
Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care.

Exclusion Criteria:

Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study.
Dementia other than Alzheimers disease.
Any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor.
Intervention: Cholecalciferol
Trial phase: Not Applicable
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Vitamin D 200,000 IU per week for 3 weeks
Eligibility criteria:
Inclusion Criteria

Patients with patients with end-stage renal disease (ESRD) who are suitable candidates for AVF creation (as assessed by pre-operative vein mapping) and plan to undergo AVF creation are eligible to participate
Study subjects must agree to participate in the study and provide written informed consent
Age: Study subjects must be > 18 years old
Sites: Emory University affiliated hospitals (including Emory University Hospital, Emory Midtown Hospital, Grady Memorial Hospital) and Emory University affiliated outpatient dialysis units
Informed consent requirements: All study subjects must agree to participate in the study and provide written informed consent.

Exclusion Criteria

Age < 18 years
Patients with a corrected serum calcium > 10.5 mg/dL within 4 weeks of study screening
Current intake of > 2000 IU per day of Vitamin D3
Subjects unable to provide informed consent or who plan to relocate outside of Atlanta during the study duration
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: ropivicaine 0.1% infusion at 12 mL/hour
Eligibility criteria:
Inclusion Criteria:

Primary, unilateral hip arthroplasty
age greater than or equal to 18 years
postoperative analgesic plan includes perineural local anesthetic infusion

Exclusion Criteria:

morbid obesity as defined by a body mass index greater than 40
chronic high dose opioid use
history of opioid abuse
neuro-muscular deficit of the ipsilateral femoral nerve and/or quadriceps muscle
vulnerable populations i.e., children, pregnant women, or prisoners
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: ropivicaine 0.4% infusion at 3 mL/hour
Eligibility criteria:
Inclusion Criteria:

Primary, unilateral hip arthroplasty
age greater than or equal to 18 years
postoperative analgesic plan includes perineural local anesthetic infusion

Exclusion Criteria:

morbid obesity as defined by a body mass index greater than 40
chronic high dose opioid use
history of opioid abuse
neuro-muscular deficit of the ipsilateral femoral nerve and/or quadriceps muscle
vulnerable populations i.e., children, pregnant women, or prisoners
Intervention: Mirabegron
Trial phase: Phase 3
ATC code: G04BD12
SMILES: Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 432
Group description: Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Patient is willing and able to complete the micturition diary and questionnaires correctly
Patient has symptoms of overactive bladder (OAB) for ≥ 3 months
Patient must experience frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period
Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence during the 3-day micturition diary period

Exclusion Criteria:

Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control
Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor
Patient is using medications intended to treat OAB
Patient has an indwelling catheter or practices intermittent self-catheterization
Patient has diabetic neuropathy
Patient has evidence of urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs
Patient receives non-drug treatment including electro-stimulation therapy
Patient has severe hypertension
Patient has participated in a clinical study within 30 days, or had participated in any previous study with mirabegron
Patient had an average total daily urine volume > 3000 mL as recorded in the 3-day micturition diary period
Patient has serum creatinine of >150 μmol/L, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2x upper limit of normal range (ULN), or gamma-glutamyl transpeptidase (γ-GT) > 3x ULN
Patient has a clinically significant abnormal electrocardiogram (ECG)
Intervention: Mirabegron
Trial phase: Phase 3
ATC code: G04BD12
SMILES: Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 440
Group description: Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Patient is willing and able to complete the micturition diary and questionnaires correctly
Patient has symptoms of overactive bladder (OAB) for ≥ 3 months
Patient must experience frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period
Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence during the 3-day micturition diary period

Exclusion Criteria:

Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control
Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor
Patient is using medications intended to treat OAB
Patient has an indwelling catheter or practices intermittent self-catheterization
Patient has diabetic neuropathy
Patient has evidence of urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs
Patient receives non-drug treatment including electro-stimulation therapy
Patient has severe hypertension
Patient has participated in a clinical study within 30 days, or had participated in any previous study with mirabegron
Patient had an average total daily urine volume > 3000 mL as recorded in the 3-day micturition diary period
Patient has serum creatinine of >150 μmol/L, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2x upper limit of normal range (ULN), or gamma-glutamyl transpeptidase (γ-GT) > 3x ULN
Patient has a clinically significant abnormal electrocardiogram (ECG)
Intervention: Cisatracurium
Trial phase: Not Applicable
ATC code: M03AC04 | M03AC11
SMILES: COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 16
Group description: Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.

Cisatracurium : One intravenous dose: 0.2mg/kg/dose
Eligibility criteria:
Inclusion Criteria:

6 months of age to 17 years of age (not yet 18)
Male or female
English or Spanish speaking
Normal airway (Mallampati Classification )
American Society of Anesthesiology Physical Status Classification I or II
Elective surgical procedure expected to last at least 45 minutes in length
Written informed consent/assent for participation given by the parent legal guardian and subject (if applicable)

Exclusion Criteria:

< 6 months of age, > 17 years of age
Difficult airway (Mallampati Classification)

History of previous difficult intubation, suspected abnormal airway: *micrognathia

facial trauma
airway tumor
epiglottitis
retropharyngeal abscess
foreign body, etc.
Scheduled for non-elective, emergent OR procedure
Parent, legal guardian, or subject is unavailable or unwilling to consent for study participation
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 18
Group description: Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg

Normal saline : One Intravenous dose
Eligibility criteria:
Inclusion Criteria:

6 months of age to 17 years of age (not yet 18)
Male or female
English or Spanish speaking
Normal airway (Mallampati Classification )
American Society of Anesthesiology Physical Status Classification I or II
Elective surgical procedure expected to last at least 45 minutes in length
Written informed consent/assent for participation given by the parent legal guardian and subject (if applicable)

Exclusion Criteria:

< 6 months of age, > 17 years of age
Difficult airway (Mallampati Classification)

History of previous difficult intubation, suspected abnormal airway: *micrognathia

facial trauma
airway tumor
epiglottitis
retropharyngeal abscess
foreign body, etc.
Scheduled for non-elective, emergent OR procedure
Parent, legal guardian, or subject is unavailable or unwilling to consent for study participation
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Group A lidocaine infusion and bolus.

Lidocaine: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
Eligibility criteria:
Inclusion Criteria:

Age: 18-65 years
Gender: Female
ASA Physical Status I-III
Non-pregnant
Surgery: Unilateral total or segmental mastectomy
Language: English speaking
Consent: Obtained

Exclusion Criteria:

Age: Under 18 or over 65 years
ASA Physical Status >III
Pregnancy
Language: Non-English speaking
Allergy to Lidocaine or amide local anesthetics
Contraindication to succinylcholine
History and/or EKG evidence of conduction defect
Renal failure (Creatinine >1.7 mg/dL)
Patient expected to remain intubated after procedure
Chronic home opioid or steroid use
Opioid use within one week prior to procedure
Drug or alcohol abuse
Inability to use PCA
Intervention: Apidra
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCC(=O)O)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 13
Group description: insulin glulisine: Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
Eligibility criteria:
Inclusion Criteria:

current patient in the Helen DeVos Children's Hospital Diabetes Clinic;
ages 4-11 years;
prepubertal (Tanner Stage I);
diagnosed with type 1 diabetes mellitus with positive islet cell antibodies or presenting at time of diagnosis with positive serum or urine ketones and requiring insulin since diagnosis;
at least six months from date of diagnosis of type 1 diabetes mellitus;
TSH within reference range and negative transglutaminase IgA antibodies within nine months of study start;
HbA1C between 6.9 and 10% within 30 days of study start; parent or guardian able and willing to provide written informed consent prior to enrollment;
at time of study start, current insulin regimen includes multiple daily injections with insulin glargine as the basal insulin and insulin aspart or insulin lispro as the pre-meal rapid acting insulin

Exclusion Criteria:

pubertal (Tanner stage 2 or greater);
concurrent Addison's disease, celiac disease or untreated hypothyroidism; - receiving oral, injectable or inhaled steroids or immunosuppressant medications;
receiving stimulants for treatment of attention deficit disorder or attention deficit hyperactivity disorder;
intercurrent illnesses such as a fever > 101 degrees F, infection, or gastroenteritis;
use of any medication to treat diabetes other than those listed under in inclusion criteria;
potential for lack of compliance or any other issue which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
Intervention: Novolog mix 70/30
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 13
Group description: insulin aspart: Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
Eligibility criteria:
Inclusion Criteria:

current patient in the Helen DeVos Children's Hospital Diabetes Clinic;
ages 4-11 years;
prepubertal (Tanner Stage I);
diagnosed with type 1 diabetes mellitus with positive islet cell antibodies or presenting at time of diagnosis with positive serum or urine ketones and requiring insulin since diagnosis;
at least six months from date of diagnosis of type 1 diabetes mellitus;
TSH within reference range and negative transglutaminase IgA antibodies within nine months of study start;
HbA1C between 6.9 and 10% within 30 days of study start; parent or guardian able and willing to provide written informed consent prior to enrollment;
at time of study start, current insulin regimen includes multiple daily injections with insulin glargine as the basal insulin and insulin aspart or insulin lispro as the pre-meal rapid acting insulin

Exclusion Criteria:

pubertal (Tanner stage 2 or greater);
concurrent Addison's disease, celiac disease or untreated hypothyroidism; - receiving oral, injectable or inhaled steroids or immunosuppressant medications;
receiving stimulants for treatment of attention deficit disorder or attention deficit hyperactivity disorder;
intercurrent illnesses such as a fever > 101 degrees F, infection, or gastroenteritis;
use of any medication to treat diabetes other than those listed under in inclusion criteria;
potential for lack of compliance or any other issue which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
Intervention: Ranolazine
Trial phase: Not Applicable
ATC code: C01EB18
SMILES: COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.

Ranolazine: Ranolazine, 1000 mg, capsule, twice daily, by mouth.
Eligibility criteria:
Inclusion Criteria:

Males or females greater than 40 years of age.
Documented peripheral arterial disease
Stable lower extremity intermittent claudication (Rutherford class 1-3) for 3 months.

Exclusion Criteria:

Critical limb ischemia (Rutherford class 4-6).
Percutaneous or surgical lower extremity revascularization within last 12 months.
Myocardial infarction within the last 6 months.
cardiac surgery within the last 6 months.
Unstable angina
Stable chronic angina
New York Heart Association Class II-IV heart failure
Left ventricular ejection fraction less than or equal to 35%
Venous thromboembolism within the last 6 months.
Uncontrolled high blood pressure, defined as systolic blood pressure greater than or equal to 180 mmHg or diastolic blood pressure greater than or equal to 110 mmHg.
Allergy to ranolazine.
corrected QT interval (QTc) greater than or equal to 440 ms in males or 460 ms in females.
Pregnant or nursing females.
Chronic dialysis therapy.
Significant liver impairment (defined as transaminases greater than or equal to 3 times the upper limit of normal) within the last 6 months.
Concomitant use of Cytochrome P450-3A (CYP3A) inhibitors
Concomitant use of CYP3A inducers
QTc prolonging agents
Orthopedic or neurologic disorders that prevent treadmill walking.
Current participation in a structured exercise program.
Intervention: Paricalcitol
Trial phase: Not Applicable
ATC code: H05BX02
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)/C=C/[C@H](C)C(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Paricalcitol: paricalcitol 1 mcg QD x 8 weeks
Eligibility criteria:
Inclusion Criteria:

Males or females ≥ 18 years of age at the start of screening
CKD with eGFR 15-60 mL/min/1.73m2 by MDRD
Not expected to start dialysis for 4 months
Serum intact PTH 70-200 pg/mL during screening period
On stable ACEI/ARB regimen for 30 days prior to screening

Exclusion Criteria:

History of any of the following diseases:

congestive heart failure
MI within the last 6 months
history of cerebrovascular accident
significant valvular disease
malignancy
Currently taking any vitamin D products
Mean systolic blood pressure values > 190 or diastolic blood pressure values > 100 mm/Hg during the preceding 30 day period prior to screening
Currently being titrated on therapy with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker
Two consecutive serum calcium values greater than 10.2 mg/dL or Ca x P > 55 mg2/dL2
Currently receiving erythropoiesis stimulating agent or intravenous iron therapy
Pregnant or breastfeeding
Intervention: Perindopril
Trial phase: Not Applicable
ATC code: C09AA04 | C09BA04 | C09BB04 | C09BX01 | C09BX02 | C09BX04 | C10BX11 | C10BX12 | C10BX13 | C10BX14 | C10BX15
SMILES: [H][C@@]12CCCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(=O)O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Active compound
Eligibility criteria:
Inclusion Criteria:

Patients with chronic subdural hematoma that needs surgical evacuation
Age > 18 year

Exclusion Criteria:

Lack of compliance
Kidney artery stenosis
Stenosis of the aorta
Severely decreased kidney function
Allergy or intolerance/contraindications toward ACE inhibitors
Already in ACE inhibitor treatment
Coagulopathies
Malignant disorders
Fertile women
Other neurological disorders
Treatment with pharmaceuticals contraindicating treatment with ACE inhibitors